Search Results | Blood | American Society of Hematology

1-20 of 737

Sort by

Sort Order Select

Journal Articles

SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation

Blood (2021) 138 (12): 1019–1033.

DOI: https://doi.org/10.1182/blood.2020008629

Published: 2021

Includes: Supplemental data

Journal Articles

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Hai Vu Nguyen, Cassandra J. Vandenberg, Ashley P. Ng, Mikara R. Robati, Natasha S. Anstee, Joel Rimes, Edwin D. Hawkins, Suzanne Cory

Blood (2020) 135 (13): 1019–1031.

DOI: https://doi.org/10.1182/blood.2019003014

Published: 2020

Includes: Supplemental data

Journal Articles

Utility of Newborn Screening for Severe Combined Immunodeficiency and X-Linked Agammaglobulinemia Using TREC and KREC Assays

Manabu Wakamatsu, MD, Hideki Muramatsu, MD PhD, Shinsuke Kataoka, MD, Yusuke Okuno, MD PhD, Sakai Yoshimi, Yoko Nakajima, MD PhD, Tetsuya Ito, MD PhD, Ikuya Tsuge, MD PhD, Seiji Kojima, MD PhD, Yoshiyuki Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 3604.

DOI: https://doi.org/10.1182/blood-2019-126669

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

DOI: https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

DOI: https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

DOI: https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Christian Grommes, MD, Igor Gavrilovic, MD, Alexandra M Miller, MD PhD, Jacqueline B Stone, MD, Thomas Kaley, MD, Juli T Madzsar, Alyssa Schumpp, Brittany T Butler, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2019) 134 (Supplement_1): 1598.

DOI: https://doi.org/10.1182/blood-2019-126214

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

DOI: https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Christopher M Melén, MD, Magali Merrien, MSc, Agata Wasik, MSc, PhD, Kristina Sonnevi, MD PhD, Henna-Riikka Junlén, MD, Birger Christersson, MD PhD, Birgitta Sander, MD PhD Prof., Björn E Wahlin, MD PhD

Blood (2019) 134 (Supplement_1): 5487.

DOI: https://doi.org/10.1182/blood-2019-126693

Published: 2019

Journal Articles

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Edward Briercheck, MD, Marcos Mauricio Siliézar Tala, MD, Yasodha Natkunam, MD PhD, David M. Weinstock, MD, Oscar Silva, MD PhD

Blood (2019) 134 (Supplement_1): 5278.

DOI: https://doi.org/10.1182/blood-2019-131620

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

DOI: https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

DOI: https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

DOI: https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

DOI: https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

DOI: https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

DOI: https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 926.

DOI: https://doi.org/10.1182/blood-2019-125871

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

DOI: https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

DOI: https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Tomoya Muto, MD PhD, Maria Guillamot, PhD, Jing Fang, MD PhD, Luna Zea Redondo, MS, Kwangmin Choi, PhD, Yixiao Gong, MSc, Callum S Walker, MSc, Kathleen Hueneman, Lyndsey C Bolanos, BSc, Laura Barreyro, PhD, Lynn Lee, MD, Kenneth D Greis, PhD, Alireza Khodadadi-Jamayran, M.Sc., Amaia Lujambio, PhD, Scott W. Lowe, PhD, Iannis Aifantis, PhD, Daniel T. Starczynowski, PhD

Blood (2019) 134 (Supplement_1): 727.

DOI: https://doi.org/10.1182/blood-2019-121423

Published: 2019

NARROW

SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Utility of Newborn Screening for Severe Combined Immunodeficiency and X-Linked Agammaglobulinemia Using TREC and KREC Assays

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only